12 research outputs found
Heavy flavour energy loss from AdS/CFT: A novel diffusion coefficient
Two AdS/CFT based energy loss models are used to compute the suppression and
azimuthal correlations of heavy quarks in heavy ion collisions. The model with
a velocity independent diffusion coefficient is in good agreement with B and D
meson data up to high . The partonic azimuthal correlations we calculate
exhibit an order of magnitude difference in low momentum correlations to pQCD
calculations [arXiv:1305.3823]. We thus propose heavy flavour momentum
correlations as a distinguishing observable of weakly- and strongly-coupled
energy loss mechanisms.Comment: 4 pages, 2 figures. Proceedings for Strangeness in Quark Matter 2017.
arXiv admin note: text overlap with arXiv:1703.0584
Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer
OBJECTIVES: Targeted biopsy, using magnetic resonance (MR) – ultrasound (US) fusion, may allow tracking of specific cancer sites in the prostate. We aimed to evaluate initial use of the technique to follow tumor sites in men on active surveillance of prostate cancer. METHODS AND MATERIALS: Fifty-three men with prostate cancer (all T1c) underwent re-biopsy of 74 positive biopsy sites, which were tracked and targeted using the Artemis MR-US fusion device (Eigen, Grass Valley, CA, USA) from March 2010 through January 2013. The initial biopsy included 12 cores from a standard template (mapped by software) and directed biopsies from regions of interest seen on MRI. In the repeat biopsy, samples were taken from sites containing cancer at the initial biopsy. Outcomes of interest at second MR-US biopsy included (a) presence of any cancer and (b) presence of clinically significant cancer. RESULTS: All cancers on initial biopsy were either Gleason score 3+3=6 (N=63) or 3+4=7 (N=11). At initial biopsy, 23 cancers were within an MRI target, and 51 were found on systematic biopsy. Cancer detection rate on repeat biopsy (29/74, 39%) was independent of Gleason score on initial biopsy (p=NS) but directly related to initial cancer core length (CCL) (p<0.02). Repeat sampling of cancerous sites within MRI targets was more likely to show cancer than re-sampling of tumorous systematic sites (61% vs. 29%, p=0.005). When initial CCL was ≥4 mm within an MRI target, over 80% (5/6) of follow-up tracking biopsies were positive. An increase of Gleason score was uncommon (9/74, 12%). CONCLUSIONS: Monitoring of specific prostate cancer-containing sites may be achieved in some men using an electronic tracking system. The chances of finding tumor on repeat specific-site sampling was directly related to the length of tumor in the initial biopsy core and presence of tumor within an MRI target; upgrading of Gleason score was uncommon. Further research is required to evaluate the potential utility of site-specific biopsy tracking for prostate cancer patients on active surveillance
Magnetic Resonance Sentinel Lymph Node Imaging of the Prostate with Gadofosveset Trisodium–Albumin
Evaluation of prostate segmentation algorithms for MRI: the PROMISE12 challenge
Prostate MRI image segmentation has been an area of intense research due to the increased use of MRI as a modality for the clinical workup of prostate cancer. Segmentation is useful for various tasks, e.g. to accurately localize prostate boundaries for radiotherapy or to initialize multi-modal registration algorithms. In the past, it has been difficult for research groups to evaluate prostate segmentation algorithms on multi-center, multi-vendor and multi-protocol data. Especially because we are dealing with MR images, image appearance, resolution and the presence of artifacts are affected by differences in scanners and/or protocols, which in turn can have a large influence on algorithm accuracy. The Prostate MR Image Segmentation (PROMISE12) challenge was setup to allow a fair and meaningful comparison of segmentation methods on the basis of performance and robustness. In this work we will discuss the initial results of the online PROMISE12 challenge, and the results obtained in the live challenge workshop hosted by the MICCAI2012 conference. In the challenge, 100 prostate MR cases from 4 different centers were included, with differences in scanner manufacturer, field strength and protocol. A total of 11 teams from academic research groups and industry participated. Algorithms showed a wide variety in methods and implementation, including active appearance models, atlas registration and level sets. Evaluation was performed using boundary and volume based metrics which were combined into a single score relating the metrics to human expert performance. The winners of the challenge where the algorithms by teams Imorphics and ScrAutoProstate, with scores of 85.72 and 84.29 overall. Both algorithms where significantly better than all other algorithms in the challenge (p<0.05p<0.05) and had an efficient implementation with a run time of 8 min and 3 s per case respectively. Overall, active appearance model based approaches seemed to outperform other approaches like multi-atlas registration, both on accuracy and computation time. Although average algorithm performance was good to excellent and the Imorphics algorithm outperformed the second observer on average, we showed that algorithm combination might lead to further improvement, indicating that optimal performance for prostate segmentation is not yet obtained. All results are available online at http://promise12.grand-challenge.org/
